Skip to main content

Advertisement

Table 7 Comparison of medical costs of BT-naïve patients between the persistent (P) and non-persistent (NP) group

From: Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database

  ADL IFX UST Total
  P NP Δ P NP Δ P NP Δ P NP Δ
Number of patients 4 10   6 13   23 7   33 31  
Cost (pre) ¥360 ¥367 ¥7 ¥1062 ¥848 - ¥214 ¥597 ¥621 ¥24 ¥653 ¥629 - ¥24
In 1000 JPY unit IP ¥0 ¥0 ¥0 ¥603 ¥249 - ¥354 ¥201 ¥36 - ¥165 ¥250 ¥122 - ¥128
OP ¥263 ¥81 - ¥182 ¥398 ¥198 - ¥200 ¥211 ¥232 ¥21 ¥251 ¥166 - ¥85
RX ¥97 ¥286 ¥189 ¥61 ¥401 ¥340 ¥186 ¥353 ¥167 ¥152 ¥341 ¥189
Cost (increase) ¥2433 ¥1621 - ¥812 ¥2246 ¥2608 ¥362 ¥2211 ¥2254 ¥43 ¥2244 ¥2126 -¥118
In 1000 JPY unit IP ¥0 ¥204 ¥204 -¥174 ¥1005 ¥1179 -¥98 ¥414 ¥512 -¥100 ¥577 ¥677
OP ¥2460 ¥946 - ¥1514 ¥2446 ¥1756 -¥690 ¥2380 ¥2021 -¥359 ¥2402 ¥1499 -¥903
RX -¥27 ¥471 ¥498 -¥26 -¥153 -¥127 -¥71 -¥180 -¥109 -¥57 ¥50 ¥107
  1. P persistent, NP non-persistent, Δ costs of NP minus costs of P, ADL Adalimumab, IFX Infliximab, UST Ustekinumab, pre:12 months pre-initiation, increase: increase from pre to post 12 months post-initiation, JPY Japanese Yen, IP inpatient medical costs, OP outpatient medical cost, RX costs of drugs other than BTs